Medically reviewed by Suzanne Fisher, RD If you’re one of the 85% of American adults who drink alcohol, whether occasionally ...

Pharmac is funding new medicine for people with ADHD and narcolepsy, and removing the renewal criteria for funded treatments.

Pharmac has announced it'll fund new stimulant medicine lisdexamfetamine from December. The medicine -- branded as Vyvanse -- is taken once a day. Chief medical officer, David Hughes, says it's a ...

Pharmac is funding new medicine for people with attention deficit hyperactivity disorder (ADHD) and narcolepsy, and removing ...

From 1 December 2024, Pharmac is also removing the renewal criteria for methylphenidate, dexamfetamine and modafinil, medicines used to treat ADHD and narcolepsy. This means that once an initial ...

Viatris reports Q3 2024 net sales of $3.74 billion, beating estimates. Adjusted EPS at $0.75 surpasses $0.68 consensus. 2024 ...

Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.

“I unmatched him,” she says. “Obviously didn’t send it.” To conclude, Dr. Buchanan said she hopes her surprise prescription ...

US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Kubapharm.com was issued a warning letter by the FDA on March 30, 2022 for selling drugs without requiring a prescription and lacking DEA registration on the website. The screenshot taken October ...

Circle to Search is coming to compatible phones with OxygenOS 15 The update also adds new boot animation, icons, and shelf card choices OxygenOS 15 introduces Gemini-powered AI Notes ...